vs

Side-by-side financial comparison of AMPCO PITTSBURGH CORP (AP) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $104.4M, roughly 1.5× AMPCO PITTSBURGH CORP). On growth, AMPCO PITTSBURGH CORP posted the faster year-over-year revenue change (11.5% vs 7.5%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -2.6%).

Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

AP vs BCRX — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.5× larger
BCRX
$156.4M
$104.4M
AP
Growing faster (revenue YoY)
AP
AP
+4.0% gap
AP
11.5%
7.5%
BCRX
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
-2.6%
AP

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AP
AP
BCRX
BCRX
Revenue
$104.4M
$156.4M
Net Profit
$-57.7M
Gross Margin
Operating Margin
-54.0%
13.6%
Net Margin
-55.2%
Revenue YoY
11.5%
7.5%
Net Profit YoY
-1958.9%
EPS (diluted)
$-2.87
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AP
AP
BCRX
BCRX
Q1 26
$156.4M
Q4 25
$104.4M
$406.6M
Q3 25
$103.7M
$159.4M
Q2 25
$108.9M
$163.4M
Q1 25
$99.2M
$145.5M
Q4 24
$93.6M
$131.5M
Q3 24
$92.1M
$117.1M
Q2 24
$107.1M
$109.3M
Net Profit
AP
AP
BCRX
BCRX
Q1 26
Q4 25
$-57.7M
$245.8M
Q3 25
$-2.2M
$12.9M
Q2 25
$-7.3M
$5.1M
Q1 25
$1.1M
$32.0K
Q4 24
$3.1M
$-26.8M
Q3 24
$-2.0M
$-14.0M
Q2 24
$2.0M
$-12.7M
Gross Margin
AP
AP
BCRX
BCRX
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
AP
AP
BCRX
BCRX
Q1 26
13.6%
Q4 25
-54.0%
64.0%
Q3 25
1.1%
18.6%
Q2 25
-2.8%
18.2%
Q1 25
3.9%
14.6%
Q4 24
5.5%
-3.4%
Q3 24
2.0%
6.6%
Q2 24
4.7%
8.0%
Net Margin
AP
AP
BCRX
BCRX
Q1 26
Q4 25
-55.2%
60.5%
Q3 25
-2.1%
8.1%
Q2 25
-6.7%
3.1%
Q1 25
1.2%
0.0%
Q4 24
3.3%
-20.4%
Q3 24
-2.1%
-12.0%
Q2 24
1.9%
-11.6%
EPS (diluted)
AP
AP
BCRX
BCRX
Q1 26
$0.00
Q4 25
$-2.87
$1.13
Q3 25
$-0.11
$0.06
Q2 25
$-0.36
$0.02
Q1 25
$0.06
$0.00
Q4 24
$0.16
$-0.13
Q3 24
$-0.10
$-0.07
Q2 24
$0.10
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AP
AP
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$10.7M
$259.0M
Total DebtLower is stronger
$117.9M
Stockholders' EquityBook value
$32.6M
Total Assets
$495.4M
$465.1M
Debt / EquityLower = less leverage
3.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AP
AP
BCRX
BCRX
Q1 26
$259.0M
Q4 25
$10.7M
$274.7M
Q3 25
$15.0M
$212.9M
Q2 25
$9.9M
$260.0M
Q1 25
$7.1M
$295.1M
Q4 24
$15.4M
$320.9M
Q3 24
$11.8M
$96.8M
Q2 24
$7.9M
$78.4M
Total Debt
AP
AP
BCRX
BCRX
Q1 26
Q4 25
$117.9M
Q3 25
$119.0M
Q2 25
$115.9M
Q1 25
$115.0M
Q4 24
$116.4M
Q3 24
$116.0M
Q2 24
$119.4M
Stockholders' Equity
AP
AP
BCRX
BCRX
Q1 26
Q4 25
$32.6M
$-119.2M
Q3 25
$60.1M
$-387.9M
Q2 25
$62.7M
$-421.6M
Q1 25
$64.6M
$-451.9M
Q4 24
$58.9M
$-475.9M
Q3 24
$61.3M
$-468.6M
Q2 24
$58.0M
$-475.6M
Total Assets
AP
AP
BCRX
BCRX
Q1 26
$465.1M
Q4 25
$495.4M
$514.2M
Q3 25
$524.4M
$446.4M
Q2 25
$537.2M
$457.2M
Q1 25
$536.2M
$480.0M
Q4 24
$530.9M
$490.4M
Q3 24
$547.4M
$491.3M
Q2 24
$560.8M
$472.4M
Debt / Equity
AP
AP
BCRX
BCRX
Q1 26
Q4 25
3.61×
Q3 25
1.98×
Q2 25
1.85×
Q1 25
1.78×
Q4 24
1.98×
Q3 24
1.89×
Q2 24
2.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AP
AP
BCRX
BCRX
Operating Cash FlowLast quarter
$2.7M
Free Cash FlowOCF − Capex
$-64.0K
FCF MarginFCF / Revenue
-0.1%
Capex IntensityCapex / Revenue
2.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AP
AP
BCRX
BCRX
Q1 26
Q4 25
$2.7M
$292.0M
Q3 25
$6.3M
$41.6M
Q2 25
$-2.3M
$41.3M
Q1 25
$-5.3M
$-27.5M
Q4 24
$7.5M
$-5.2M
Q3 24
$11.4M
$8.2M
Q2 24
$-5.3M
$-1.4M
Free Cash Flow
AP
AP
BCRX
BCRX
Q1 26
Q4 25
$-64.0K
$291.2M
Q3 25
$3.3M
$40.3M
Q2 25
$-3.8M
$41.1M
Q1 25
$-7.5M
$-27.7M
Q4 24
$3.7M
$-5.9M
Q3 24
$8.4M
$8.2M
Q2 24
$-8.0M
$-1.5M
FCF Margin
AP
AP
BCRX
BCRX
Q1 26
Q4 25
-0.1%
71.6%
Q3 25
3.2%
25.3%
Q2 25
-3.5%
25.2%
Q1 25
-7.5%
-19.0%
Q4 24
4.0%
-4.5%
Q3 24
9.1%
7.0%
Q2 24
-7.5%
-1.4%
Capex Intensity
AP
AP
BCRX
BCRX
Q1 26
Q4 25
2.7%
0.2%
Q3 25
2.9%
0.8%
Q2 25
1.3%
0.1%
Q1 25
2.2%
0.1%
Q4 24
4.0%
0.5%
Q3 24
3.2%
0.1%
Q2 24
2.5%
0.1%
Cash Conversion
AP
AP
BCRX
BCRX
Q1 26
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-4.62×
-859.91×
Q4 24
2.40×
Q3 24
Q2 24
-2.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AP
AP

Forged And Cast Mill Rolls$67.0M64%
Air Handling Systems$14.3M14%
Heat Exchange Coils$13.1M13%
Centrifugal Pumps$10.3M10%
Forged Engineered Products$4.0M4%

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

Related Comparisons